Rx Name [ZIDOVUDINE, 08180820]

Rx Name	RETROVIR 10MG/ML INJ (GSK/COL) ZIDOVUDINE
Active Ingredient	ZIDOVUDINE
Therapeutic Code	08180820
Therapeutic Class	NRTI
Indications	In combination with other antiretroviral agents for the treatment of HIV infection. Zidovudine is also indicated for the prevention of maternal to fetal HIV transmission during gestation, labor and to the neonate after birth.
Caution	Bone marrow suppression (anemia and/or neutropenia), nausea, vomiting, anorexia, headache, malaise, asthenia and insomnia occur. Concurrent use of zidovudine and alpha-interferon, dapsone, vincristine, doxorubicin, ganciclovir or vinblastine may result in life threatening hematologic toxicities e.g. Anemia and neutropenia. Use with caution in patients taking interferon-Beta, valproic acid, paracetamol, stavudine or rifabutin.
Dose Range	Adult: 600mg daily in divided doses in combination with other antiretroviral agents. Pediatric: 6 weeks to 12 years: 160mg/square meter orally every 8 hours (maximum dose, 200 mg every 8 hours) in combination with other antiretroviral agents. To prevent
Drug Interactions
Pregnancy
Breast Feeding	The Centers for Disease Control and Prevention (CDC) and other experts recommend that HIV-infected women not breast-feed infants, regardless of antiretroviral therapy due to the risk of transmitting the virus through breastfeeding.
Drug Note